Neuspera Medical

Neuspera Medical operates in implantable neuromodulation and medical devices, with an initial commercial focus on urinary urge incontinence. Its principal differentiation is architectural: the integrated sacral neuromodulation system uses a miniaturized implant powered by a wearable external battery rather than a permanently implanted battery. The company also pairs the implant with a smartphone patient controller and an iPad-based clinician programmer. Its Mid-Field Powering technology is designed to transfer energy to implants at depths of 10 centimeters or more, supporting applications that conventional externally powered approaches may not address. The available company profile does not identify named direct competitors, so competitive comparisons are best made against legacy implantable sacral neuromodulation systems and other peripheral nerve stimulation approaches. Neuspera's FDA approval on Jun 18, 2025, pivotal trial reporting in March 2026, and proposed 2027 Medicare payment parity give it regulatory and reimbursement milestones that distinguish it from earlier-stage device developers. Its focus remains narrower than broad digital health companies, but its platform could extend into additional neuromodulation indications, including chronic peripheral nerve pain.

Neuspera's growth trajectory shows a long device-development cycle followed by a recent regulatory and commercial inflection point. The company was founded on Dec 3, 2013 and raised $8,888,888 in a 2016 venture round, followed by $26 million in 2018, $12 million in 2019, and a $65 million Series C in 2021. Its $23 million Series D on Jul 15, 2024 brought cumulative recorded funding to $134,888,888 across seven rounds, with Treo Ventures and Vertex Ventures HC leading both the Series C and Series D. The Jun 18, 2025 FDA approval of its integrated sacral neuromodulation system shifted the company from primarily development-stage activity toward commercialization. Subsequent milestones include a replacement case and FREEDOM Registry activity in February 2026, 12-month pivotal trial results in March 2026, and proposed Medicare payment parity announced in July 2026. Hiring signals point to operational build-out, including a COO, supply chain director, and controller. The main uncertainty is scale: the employee band remains 11-50 and the 2025 venture round has no disclosed amount.